KALV
NASDAQ
US
KalVista Pharmaceuticals, Inc. - Common Stock
$19.90
▲ +$0.13
(+0.66%)
Vol 910K
3
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$816.3M
ROE
-237.5%
Margin
-724.8%
D/E
1600.22
Beta
-0.15
52W
$7–$17
Wall Street Consensus
15 analysts · Apr 20266
Strong Buy
8
Buy
1
Hold
0
Sell
0
Strong Sell
93.3%
Buy Rating
Price Chart
Similar Stocks
Earnings
Beat rate: 80.0%| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Dec 2025 | $-0.48 | $0.92 | +$1.40 |
| Mar 2025 | $-0.89 | $-0.78 | +$0.11 |
| Dec 2024 | $-0.93 | $-0.91 | +$0.02 |
| Sep 2024 | $-0.93 | $-0.87 | +$0.06 |
Quarterly Revenue & Earnings
| Quarter | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… | 2025-0… |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | $1.4M | $13.7M |
| Net Income | — | -$42.3M | -$48.5M | -$52.2M | -$60.1M | -$49.5M |
Fundamentals Trend
| Metric | 2025-07-31 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -117.1% | -103.9% | -117.1% | -117.1% | -117.1% | -237.5% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | -4214.3% | -229.4% | -4214.3% | -4214.3% | -4214.3% | -724.8% |
| Gross Margin | 58.6% | — | — | — | — | — |
| D/E Ratio | 324.40 | 111.00 | 324.40 | 324.40 | 324.40 | 1600.22 |
| Current Ratio | 5.37 | 5.35 | 5.37 | 5.37 | 5.37 | 7.22 |
Key Ratios
ROA (TTM)
-63.6%
P/S (TTM)
54.00
P/B
7.2
EPS (TTM)
$-2.95
CF/Share
$-3.11
52W High
$17.30
52W Low
$7.30
$7.30
52-Week Range
$17.30
Financial Health
Free Cash Flow
-$54.9M
Net Debt
-$93.9M
Cash
$243.5M
Total Debt
$149.6M
As of Sep 30, 2025
How does KALV compare to Biotechnology peers?
Peer group: Micro-cap Biotechnology (All) · 528 companies
KALV valuation vs Biotechnology peers
P/E ratio
—
▼
0%
below
peers
(18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
54.0
▲
320%
above
peers
(12.9)
vs Peers
vs Industry
Pricier
P/B ratio
7.2
▲
192%
above
peers
(2.5)
vs Peers
vs Industry
Overvalued
Div yield
—
▼
0%
below
peers
(0.0%)
vs Peers
vs Industry
Low yield
KALV profitability vs Biotechnology peers
ROE
-237.5%
▼
253%
below
peers
(-67.3%)
vs Peers
vs Industry
Weak
Net margin
-724.8%
▼
153%
below
peers
(-286.8%)
vs Peers
vs Industry
Weak
Gross margin
—
▼
0%
below
peers
(78.6%)
vs Peers
vs Industry
In line
ROA
-63.6%
▼
36%
below
peers
(-46.7%)
vs Peers
vs Industry
Weak
KALV financial health vs Biotechnology peers
D/E ratio
1600.2
▼
0%
below
peers
(0.0)
vs Peers
vs Industry
High debt
Current ratio
7.2
▲
63%
above
peers
(4.4)
vs Peers
vs Industry
Below avg
Beta
-0.2
▼
116%
below
peers
(1.0)
vs Peers
vs Industry
More volatile
KALV fundamentals radar
KALV
Peer median
Industry
KALV profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
KALV vs peers: key metrics
Latest News
No related news yet